Pricing Log in Create free account

Genelux Corporation (GNLX) vs Inovio Pharmaceuticals, Inc. (INO)

Genelux Corporation and Inovio Pharmaceuticals, Inc. are both Biotechnology companies. Genelux Corporation and Inovio Pharmaceuticals, Inc. are of similar size ($112.2M and $107.5M). Across the 11 metrics below, Genelux Corporation leads on 8 and Inovio Pharmaceuticals, Inc. on 3.

Valuation

Metric GNLX INO Biotechnology median
P/E n/m n/m 8.50
P/S 9.67 209.44 9.71
P/B 6.75 18.49 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 8.77 157.45 9.21
Earnings yield (35.54%) (91.92%) (33.15%)
Free cash flow yield (26.36%) (99.09%) (25.50%)

Profitability

Metric GNLX INO Biotechnology median
Gross margin (3.42%) 100.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (177.93%) (409.87%) (56.36%)
Return on assets (121.80%) (114.64%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric GNLX INO Biotechnology median
Revenue growth (TTM) — (54.82%) 6.02%
EPS growth (last fiscal year) 9.47% 54.18% 30.26%
Revenue growth, 5-year CAGR — (61.18%) 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric GNLX INO Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.39 1.00 4.72
Net debt to EBITDA 0.44 0.70 0.96

Dividend

Metric GNLX INO Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric GNLX INO Biotechnology median
Market cap 112.21m 107.53m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack